Literature DB >> 7199324

Excretion and metabolism of 14C-midazolam in humans following oral dosing.

P Heizmann, W H Ziegler.   

Abstract

After oral dosing of 10 mg 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4] benzodiazepine (midazolam, Ro 21-3981, Dormicum) labelled with 14C (25 microCi) to 4 human volunteers, the total radioactivity is mainly excreted via the kidneys. Nearly 90% are excreted within 24 h. Main urinary metabolite is the conjugated 1-hydroxymethyl derivative, which amounts to 60-70% of the administered dose within 24 h. Compared to total radioactivity, levels of unchanged drug in plasma are rather low and differ from one subject to the next. Most of the plasma radioactivity consists of the 1-hydroxymethyl compound, most of it in conjugated form. Levels of free metabolite are lower than those of unchanged drug. Radioactivity is rapidly eliminated from plasma. The results of the present oral study seem to indicate significant first-pass metabolism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7199324

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  31 in total

Review 1.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

3.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; F Ma; Y Wang; C Smith
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  The pharmacokinetics of midazolam in patients with congestive heart failure.

Authors:  I H Patel; P P Soni; E K Fukuda; D F Smith; C V Leier; H Boudoulas
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

7.  Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.

Authors:  Vibeke Andersen; Natalie Pedersen; Niels-Erik Larsen; Jesper Sonne; Steen Larsen
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

8.  Effect of hepatic function on the EC50 of midazolam and the BIS50 at the time of loss of consciousness.

Authors:  Yu-hong Li; Rui He; Jin-guang Ruan
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

9.  A comparison of oral midazolam, nitrazepam and placebo in young and elderly subjects.

Authors:  C M Castleden; J G Allen; J Altman; P St John-Smith
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Ontogeny of midazolam glucuronidation in preterm infants.

Authors:  Saskia N de Wildt; Greg L Kearns; Darryl J Murry; Gideon Koren; John N van den Anker
Journal:  Eur J Clin Pharmacol       Date:  2009-10-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.